Background: Relevant to trauma induced coagulopathy (TIC) diagnostics, microfluidic assays allow controlled hemodynamics for testing of platelet and coagulation function using whole blood.
BACKGROUND
Trauma is the leading cause of death in people under the age of 36 years old (1) . Many severely injured patients exhibit trauma induced coagulopathy (TIC), a hemorrhagic state that accounts for 40% of trauma deaths (1) . TIC is multifactorial and associated with tissue injury, inflammation, shock, hemodilution, acidosis, hypoxia, and hypothermia (1) . Tissue injury and shock result in hyperfibrinolysis due to the acute release of tissue plasminogen activator (tPA) from endothelial cells. Systemic fibrinolysis results in fibrinogen consumption and limits clot formation and stability at the site of vascular injury, resulting in increased bleeding risk (2) . Furthermore, blood loss followed by resuscitation with colloids or packed red blood cells (PRBCs) leads to the hemodilution of clotting factors.
Most research in TIC has focused on coagulation factors and proteases, with the role of platelet function during trauma not as well studied (3, 4) . Platelet function studies of trauma patients have been difficult to implement due to the technical complexities of current platelet function tests.
Although recent advances in platelet aggregometry and thromboelastography (TEG) have enabled important studies of platelet function and clot strength in trauma patients (5) (6) (7) (8) (9) . These techniques, however, are closed systems lacking flow or presenting poorly defined flow fields.
Microfluidic systems are open systems where blood flows over a zone of defined procoagulant surface, thereby recreating the unique spatial and compositional attributes of blood clotting found in vivo (10) . Microfluidic technology in conjunction with micropatterning techniques enable low volume and high throughput testing of platelet function and fibrin generation over a range of physiological shear stresses (11) (12) (13) (14) (15) . Microfluidic whole blood assays have been previously used to evaluate platelet and clotting function in hemophiliacs and healthy donors taking antiplatelet therapeutics (10, (16) (17) (18) .
In regards to current resuscitation strategies, the administration of PRBCs with or without fresh frozen plasma (FFP) and the optimal FFP:PRBCs ratio remain active areas of investigation (19) .
Prospective studies have shown that platelets may serve as the third component of resuscitation strategy (19) (20) (21) (22) . PRBC administration not only increases hemoglobin, but also contributes biorheologically by driving platelet margination towards the vessel wall.
In this study, we applied microfluidic technology to investigate resuscitation-driven hemodilution, hyperfibrinolysis, and plasmin-inhibitor therapy, all topics relevant to TIC risk and treatment. Additionally, we evaluated platelet function under flow using whole blood from trauma patients.
METHODS

Microfluidic evaluation of hemodilution and hyperfibrinolysis
Following approval from the Internal Review Board approval at the University of Pennsylvania, healthy donors (n = 15) were recruited to donate whole blood using standard phlebotomy techniques. Donors were required to refrain from all oral medications for 7 days and abstain from alcohol for 48 hours prior to donation. Blood was drawn into corn trypsin inhibitor (CTI, Microfluidic fabrication methods and device specifications were previously described (11, 17, 23) .
Microfluidic channels ran perpendicularly over a 250 µm wide strip of patterned equine fibrillar collagen type I (Chronopar, Chronolog) or Tissue factor (TF) bearing collagen type I surfaces (Dade Innovin, Siemens Healthcare USA, Malvern, PA). Epifluorescent microscopy and image acquisition were performed in real-time as previously described (10, 17) . Dilution of the hematocrit to simulate resuscitation-induced hemodilution was achieved with exogenous addition of HEPES buffered saline (HBS, 20 mM HEPES, 160 mM NaCl, pH 7.5), donor specific platelet poor plasma (PPP) or platelet rich plasma (PRP). Isolation of PRP or PPP was previously described (17, 24) . HBS, PPP or PRP was added in 1:3, 1:1, 3:1 ratio to whole blood to obtain Hct levels of 30%, 20%, 10% respectively 5 min prior to initiation of the flow assay. Fibrinolysis was promoted by exogenously adding 10X stock solutions of tPA (abcam, Cambridge, MA, 0-50 nM). Blood samples were perfused at an initial venous wall shear rate of 200 s -1 or arterial wall shear rate of 1222 s -1 in a previously designed pressure relief mode for 20 min (12) . Platelet and fibrin accumulation analysis was completed as previously described (17) .
Microfluidic Assessment of Trauma Patient Platelet Function
Following Institutional Review Board approval, blood was collected from trauma patients (n = 20)
who had sustained injuries requiring evaluation at the Hospital of University of Pennsylvania 
Statistical Significance Analysis
Statistical significance was assessed using a two-tailed unpaired Student's t-test. Data sets were considered significantly different from each other if the calculated p-value < 0.05. Exact p-values are reported in the results where p > 0.001, otherwise p < 0.001 is denoted.
RESULTS
Hemotocrit reduction: dilution reduces platelet deposition on collagen (no thrombin) and plateletfibrin accumulation on TF/collagen.
Our healthy volunteer study population had a mean age 26.2 ± 1.52y (10M/5F). The effect of hematocrit dilution on platelet deposition was evaluated by ex vivo dilution of healthy whole blood with either saline, PPP, or PRP (Supplemental Fig. 1 ). In the absence of thrombin with PPACK- 
1A,C,E).
As expected in the flow assay over collagen, fibrin generation was dependent on thrombin production and was negligible in PPACK-inhibited whole blood in the absence of surface-patterned TF on collagen (Fig. 1B, D 
, F).
Similarly, in the presence of surface-triggered coagulation ( Figure 5D, F-N) . Platelet aggregates tended to form above the initial monolayer of collagen-adherent platelets but were subsequently washed downstream. Clots formed from these patients did not grow to full channel occlusion during the duration of the 900 sec assay ( Figure 5A, black arrow) . This failure of secondary aggregation in these patients may be due to a lack of ADP or thromboxane A2 mediated clot growth. Interestingly, 3 patients exhibited hyper-responsive platelet function in this microfluidic assay with two patients forming occlusive clots within the first 400 seconds (Figure 5R-T) .
Trauma patient platelets respond less to antagonism by MRS 2179 and iloprost but increased sensitivity to inhibition by GSNO
To assess the various pathways that affect trauma platelet signaling under flow, we antagonized platelet function in three different manners (Supplemental Figure S2) . MRS 2179 was used to potently inhibit the platelet ADP receptor, P2Y1. The addition of GSNO was used to stimulate nitric oxide production ex vivo and iloprost was used to raise cyclic adenosine monophosphate 
A subpopulation of trauma patient platelets displayed decreased p-selectin expression under flow
P-selectin surface expression was also used as a marker for α-granule secretion and irreversible platelet activation in our microfluidic assay (Supplemental Figure S3) . A population of trauma patients (9/21) exhibited low p-selectin expression in the flow assay (data not shown) however, when normalized against the platelet fluorescence signal, a single patient displayed a severe deficit in p-selectin expression on a per platelet basis (Supplemental Figure S3B-D) . The lack of pselectin expression in patient #9 may be indicative of low levels of platelet activation and potential previous degranulation of platelets prior to microfluidic testing.
DISCUSSION
Trauma induced coagulopathy is a multi-faceted phenomenon that occurs in the combined setting of shock, hemodilution, hypothermia, and tissue injury. With the use of microfluidic technology we evaluated hemodilution and hyperfibrinolysis, two common mechanisms of TIC, in order to understand how derangements in platelet deposition and fibrin formation contribute to altered hemostasis. Hemodilution of healthy whole blood with saline, PPP, or PRP significantly reduced platelet adhesion to collagen in the absence of surface-triggered coagulation at all lowered Hct levels ( Figure 1) . Platelet deposition was also significantly decreased with this dilution scheme on TF-bearing collagen surfaces (Figure 2) . RBCs strongly influences platelet margination and enhances platelet accumulation at the collagen or collagen/TF injury site in these assays. These results indicate a significant role for RBCs in mediating the rapid platelet response required to seal vessel injuries. Furthermore, RBCs have also been shown to release ADP thus promoting platelet aggregation and can potentially sustain thrombin generation (25) . This is could be another role in which RBCs support platelet function and coagulation in our microfluidic assays. However, ADP release from RBC is expected to be minimal under the venous flow conditions tested (Figure 2 ).
Furthermore, a second mechanism associated with TIC is increased fibrinolytic activity. Excessive fibrinolysis impairs clot integrity and causes bleeding. We recapitulated this mechanism and rapidly detected changes in fibrin accumulation and clot stability in microfluidic assays with exogenous addition of tPA. We promoted a 'lytic state' under flow inducing fibrin lysis at venous shear rates that was rescued with ex vivo εACA addition (Figure 3) . At arterial shear rates, the 'lytic state' induced embolism as clots tore from the TF bearing collagen surfaces and washed downstream (Figure 4) . In rare cases, the 'lytic state' induced a consumptive coagulopathy with complete fibrin lysis and disintegration of platelet aggregates followed by platelet re-adherence and fibrin regeneration on the TF bearing collagen surface. This observed process depletes complete TEG test may take upward to 60 min (27) .
In whole blood microfluidic assays, on the other hand, platelet deposition and fibrin generation must occur under well-controlled hemodynamic conditions and in the presence of convective dilution of thrombin, soluble agonists, and plasma proteins. During these assays, the biorhelogic phenomena present can either limit or augment local enzyme concentrations. In addition to changes in the local enzyme concentrations, platelet receptor-ligand bonds must withstand the hydrodynamic shear stress imparted by following blood. Thus whole blood microfluidic assays provide a much more rigorous physiologic test of platelet function and fibrin generation not captured by static clotting assays and TEG (28, 29) .
To the best of our knowledge, our results are the first real-time platelet function testing of whole blood samples from trauma patients using microfluidic technology. One previous study by Jacoby Important distinctions exist between assays that evaluate platelets under non-flow conditions and microfluidics that allow platelets to accumulate on a surface to levels >200-fold that of whole blood levels. We demonstrated that microfluidic assay of trauma patient samples is a global test of whole blood clotting function under flow with the capability of detecting platelet dysfunction.
In future work, a comparison of microfluidic assay with platelet aggregometry or platelet mapping-TEG may provide further insights into platelet dysfunction during TIC. Microfluidic assay allows determination of: (1) In this study, we have used microfluidic technology to effectively evaluate current resuscitation strategies and hyperfibrinolysis showing more rapid detection of impaired hemostasis and coagulation than what is capable with current technologies. Furthermore, we also tested trauma patient platelet function using this high throughput method. The fast identification of platelet function defects in trauma patients using whole blood microfluidic assays indicate a potential novel 15 min test to help guide coagulopathy treatments in the future. 20 trauma patients were examined in microfluidic assays with PPACK-inhibited whole blood perfusion over collagen. Medications altering coagulation, blood product use, pre-existing conditions, Hct, platelet count, Injury Severity Score, diagnosis of traumatic brain injury, PT, PTT, INR, blood alcohol level, and blood products post microfluidic testing are as reported. Table 1 . 20 trauma patients were examined in microfluidic assays with PPACK-inhibited whole blood perfusion over collagen. Trauma patient characteristics and clinical data are as reported, blood products post microfluidic testing were administered within the first hour of evaluation by
TABLES
Hospital of University of Pennsylvania (HUP) Level 1 Trauma Center.
